Description

Rlam 1 mg (Alprazolam) Tablets

Rlam 1 mg is an oral pharmaceutical formulation containing alprazolam, a high-potency, short- to intermediate-acting triazolobenzodiazepine. It acts as a positive allosteric modulator at central nervous system $\text{GABA}_A$ receptor complexes. By enhancing the binding affinity of gamma-aminobutyric acid ($\text{GABA}$) to its receptor, it increases chloride ion conductance, resulting in rapid neuronal hyperpolarization and significant anxiolytic, antipanic, sedative, and central muscle-relaxant effects.

Product Overview

Primary Indications

Rlam 1 mg is prescribed under direct clinical supervision for:

• Panic Disorder: Acute and maintenance treatment of panic disorder, with or without agoraphobia, characterized by sudden, unexpected panic attacks and autonomic symptoms.

• Generalized Anxiety Disorder (GAD): Short-term management of moderate to severe generalized anxiety states, tension, and psychoneurotic apprehension.

• Anxiety Associated with Depressive Symptoms: Adjunctive short-term stabilization of anxiety symptoms presenting concomitantly with depressed mood.

Key Information & Precautions

• High-Potency Dosing: Alprazolam is extremely potent (1 mg of alprazolam has roughly the therapeutic equivalence of 10 mg to 20 mg of diazepam). Initial clinical dosing usually starts at lower strengths (0.25 mg to 0.5 mg); the 1 mg tablet is generally reserved for established, titrated regimens.

• Dependence, Tolerance, and Abuse Liability: Due to its rapid absorption, high lipophilicity, and fast-acting receptor binding, alprazolam has a high potential for psychological dependence, physiological addiction, and tolerance. Courses of therapy should be restricted to the lowest therapeutic dose for the shortest duration (typically 2 to 4 weeks).

• Severe Withdrawal and Rebound Phenomena: Inter-dose anxiety and rapid tolerance can occur. Abrupt cessation after extended use can precipitate dangerous withdrawal crises, including grand mal seizures, delirium, autonomic instability, tremors, and severe rebound panic. Discontinuation strictly mandates a gradual, physician-guided dose reduction.

• Boxed Warning — Concomitant CNS Depressants: Co-administration with opioids, alcohol, or other sedative-hypnotics substantially increases the risk of severe respiratory depression, profound sedation, coma, and fatal overdose.

• Drug Interactions (CYP3A4): Alprazolam clearance depends heavily on the CYP3A4 enzyme system. Co-administration with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) drastically elevates alprazolam blood levels, compounding the danger of toxicity.

• Psychomotor & Cognitive Impairment: Induces drowsiness, slowed reaction speed, and impaired motor coordination. Patients must be advised against driving, operating heavy machinery, or performing hazardous tasks while taking this medication.